Sun Pharma settles patent infringement case with Abraxis Bioscience

  • Posted on: 11 December 2019
  • By: PharmaTutor News

Pharma Admission

pharma admission

 

Sun Pharma Advanced Research Company Ltd. (SPARC) announced that Abraxis Bioscience LLC. has dismissed the patent infringement complaint filed against SPARC regarding SPARC's New Drug Application for PICS (Paclitaxel Injection Concentrate for Suspension).

"We are very pleased that Abraxis Bioscience LLC. has withdrawn its infringement claims paving the way for a successful launch as and when we receive necessary regulatory approvals," said Anil Raghavan, CEO of SPARC. SPARC will also inform the USFDA of the dismissal of the complaint to vacate the 30-month stay.

About PICS (Paclitaxel Injection Concentrate for Suspension):
PICS (Paclitaxel Injection Concentrate for Suspension) is a Cremophor® and Albumin-free formulation of Paclitaxel. PICS seeks the same indications as Abraxane®. Since it is Cremophor®-free, it can be diluted in either a PVC or non-PVC sterile infusion bag with an appropriate volume of 5% w/v Dextrose injection. Premedication to prevent hypersensitivity is generally not needed prior to administration of PICS. A New Drug Application for PICS is currently under review by the USFDA.

<< Back to Pharma News

Subscribe to PharmaTutor News Alerts by Email


Latest News